WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Xi Holds Talks with Tanzanian PresidentWorld Insights: Bringing ChinaChina launches campaign to boost grain outputChinese President Appoints New AmbassadorsFederation Cultivates 'Legal Docents' to Help Protect Women's RightsXi Focus: 4 Key Takeaways from Xi's Diplomacy After CPC CongressChinese President Appoints New AmbassadorsXinhua Headlines: Xi, Biden Hold Candid, InFederation Cultivates 'Legal Docents' to Help Protect Women's RightsXi Urges Efforts to Carry Forward Great Founding Spirit of CPC and Yan'an Spirit
3.6213s , 6491.078125 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Stellar Scope news portal